Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity.
Kupando has raised $11.5M in total funding. The most recent round was Series A. The last funding was announced in March 2026.
Kupando's investors include HTGF (High-Tech Gruenderfonds), Remiges Ventures, Brandenburg Kapital, Carma Fund, Ventura BioMed Investors.
Kupando is headquartered in Schönefeld, Germany.
Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity.
Kupando is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kupando — Funding & Investors." VCBacked, March 18, 2026, https://www.vcbacked.co/company/kupando. Accessed July 25, 2026.
VCBacked. (2026). Kupando — Funding & Investors. Retrieved July 25, 2026, from https://www.vcbacked.co/company/kupando
{{cite web |title=Kupando — Funding & Investors |url=https://www.vcbacked.co/company/kupando |website=VCBacked |access-date=July 25, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated